"A Manhattan Startup Delivers Gut-Friendly Meals to the Digestively Challenged" - Robin Schatz
FODMAP is an acronym referring to four classes of fermentable, short-chain carbohydrates that can particularly cause digestive upset for people with Irritable Bowel Syndrome, or IBS, and other digestive disorders. Patients with Inflammatory Bowel Disease (IBD) may also benefit from low-FODMAP diets with some modifications. That's where Epicured comes in. One of Epicured’s largest investors is Mount Sinai Ventures, the investment arm of the big Manhattan-based health system. Brent Stackhouse, managing director and vice president, said he got interested in Epicured after hearing about the company from Laura Manning, MPHD, RD, CDN, clinical nutrition coordinator at the Susan and Leonard Feinstein IBD Clinical Center at the Mount Sinai Health System. “I generally invest in things that the experts at Mount Sinai are using or are going to use.”
— Brent Stackhouse, Managing Director, Vice President, Mount Sinai Ventures
— Laura Manning, MPH, RD, CDN, Clinical Nutrition Coordinator, Susan and Leonard Feinstein IBD Clinical Center, Mount Sinai Health System